Apolipoprotein C-III in association with metabolic-dysfunction associated steatotic liver disease: A large, multicenter study

IF 6.6 2区 医学 Q1 NUTRITION & DIETETICS Clinical nutrition Pub Date : 2024-10-08 DOI:10.1016/j.clnu.2024.10.007
Matina Kouvari , Laura Valenzuela-Vallejo , Valentina Guatibonza-Garcia , Ornella Verrastro , Evangelos Axarloglou , Sophia C. Mylonakis , Jacob George , Georgios Papatheodoridis , Geltrude Mingrone , Christos S. Mantzoros
{"title":"Apolipoprotein C-III in association with metabolic-dysfunction associated steatotic liver disease: A large, multicenter study","authors":"Matina Kouvari ,&nbsp;Laura Valenzuela-Vallejo ,&nbsp;Valentina Guatibonza-Garcia ,&nbsp;Ornella Verrastro ,&nbsp;Evangelos Axarloglou ,&nbsp;Sophia C. Mylonakis ,&nbsp;Jacob George ,&nbsp;Georgios Papatheodoridis ,&nbsp;Geltrude Mingrone ,&nbsp;Christos S. Mantzoros","doi":"10.1016/j.clnu.2024.10.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>The available literature on the effect of apolipoprotein C-III (ApoC-III) inhibition in MASLD reveals inconsistencies. The aim of the present work was to examine levels of ApoC-III in the entire spectrum of metabolic-dysfunction associated steatotic liver disease (MASLD).</div></div><div><h3>Methods</h3><div>This is a multicenter study involving patients enrolled in two gastroenterology-hepatology clinics (Greece and Australia) and in a bariatric-metabolic surgery clinic (Italy), with liver biopsy before and after bariatric surgery or lifestyle modification.</div></div><div><h3>Results</h3><div>Comparing simple MASL to steatohepatitis (MASH) with fibrosis stage F ≥ 2 (at-risk MASH), revealed a marginally significant trend for decreased ApoC-III levels in the latter group (<em>p</em> = <em>0.07</em>). Multi-adjusted analysis revealed an inverse association between ApoC-III and at-risk MASH (Odds Ratio<sub>per 1 mg/dL increase in ApoC-III</sub> = 0.91, 95 % Confidence Interval (0.83, 0.99)). ApoC-III interacted with triglycerides in predicting at-risk MASH (<em>p-for-interaction</em> = <em>0.002</em>). Participants with ApoC-III &gt; median (∼3.75 mg/dL) and normal triglycerides (triglyceridese≤150 mg/dL) had the lowest likelihood to present at-risk MASH (31.8 %) in contrast with participants with ApoC-III &lt; median and hypertriglyceridemia among whom at-risk MASH was recorded in 57.1 %. In multi-adjusted analysis participants with normal triglycerides and high ApoC-III had 64 % lower odds of at-risk MASH compared with their counterparts with ApoC-III &lt; median (OR = 0.36, 95%CI (0.14, 0.86)). Among participants with hypertriglyceridemia, those with ApoC-III &lt; median had less prevalent at-risk MASH compared with those with ApoC-III ≥ median (OR = 0.54, 95%CI (0.32, 0.98)); however in all cases significance was lost when liver enzymes were taken into account.</div></div><div><h3>Conclusions</h3><div>In advanced disease stages, ApoC-III levels seem to be decreased and advanced organ damage may be a potential explanation. Mendelian randomization studies are needed to confirm or refute this hypothesis.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":null,"pages":null},"PeriodicalIF":6.6000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nutrition","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0261561424003650","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background & aims

The available literature on the effect of apolipoprotein C-III (ApoC-III) inhibition in MASLD reveals inconsistencies. The aim of the present work was to examine levels of ApoC-III in the entire spectrum of metabolic-dysfunction associated steatotic liver disease (MASLD).

Methods

This is a multicenter study involving patients enrolled in two gastroenterology-hepatology clinics (Greece and Australia) and in a bariatric-metabolic surgery clinic (Italy), with liver biopsy before and after bariatric surgery or lifestyle modification.

Results

Comparing simple MASL to steatohepatitis (MASH) with fibrosis stage F ≥ 2 (at-risk MASH), revealed a marginally significant trend for decreased ApoC-III levels in the latter group (p = 0.07). Multi-adjusted analysis revealed an inverse association between ApoC-III and at-risk MASH (Odds Ratioper 1 mg/dL increase in ApoC-III = 0.91, 95 % Confidence Interval (0.83, 0.99)). ApoC-III interacted with triglycerides in predicting at-risk MASH (p-for-interaction = 0.002). Participants with ApoC-III > median (∼3.75 mg/dL) and normal triglycerides (triglyceridese≤150 mg/dL) had the lowest likelihood to present at-risk MASH (31.8 %) in contrast with participants with ApoC-III < median and hypertriglyceridemia among whom at-risk MASH was recorded in 57.1 %. In multi-adjusted analysis participants with normal triglycerides and high ApoC-III had 64 % lower odds of at-risk MASH compared with their counterparts with ApoC-III < median (OR = 0.36, 95%CI (0.14, 0.86)). Among participants with hypertriglyceridemia, those with ApoC-III < median had less prevalent at-risk MASH compared with those with ApoC-III ≥ median (OR = 0.54, 95%CI (0.32, 0.98)); however in all cases significance was lost when liver enzymes were taken into account.

Conclusions

In advanced disease stages, ApoC-III levels seem to be decreased and advanced organ damage may be a potential explanation. Mendelian randomization studies are needed to confirm or refute this hypothesis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
载脂蛋白 C-III 与代谢功能障碍相关性脂肪肝的关系:一项大型多中心研究。
背景与目的:关于载脂蛋白C-III(ApoC-III)抑制剂在MASLD中的作用,现有文献并不一致。本研究旨在检测代谢功能障碍相关性脂肪性肝病(MASLD)整个病程中载脂蛋白 C-III 的水平:这是一项多中心研究,涉及两个胃肠病肝病诊所(希腊和澳大利亚)和一个减肥代谢外科诊所(意大利)的患者,他们在减肥手术或生活方式调整前后接受了肝活检:将单纯 MASL 与纤维化分期 F≥2 的脂肪性肝炎(MASH)(高危 MASH)进行比较,发现后一组的载脂蛋白 C-III 水平略有下降趋势(p = 0.07)。多重调整分析显示,载脂蛋白C-III与高危MASH之间呈反向关系(载脂蛋白C-III增加1毫克/分升的比值比=0.91,95%置信区间(0.83,0.99))。载脂蛋白C-III与甘油三酯在预测高危MASH方面存在交互作用(交互作用 p = 0.002)。载脂蛋白C-III>中位数(∼3.75 mg/dL)且甘油三酯正常(甘油三酯ese≤150 mg/dL)的参与者出现高危MASH的可能性最低(31.8%),与载脂蛋白C-III的参与者形成鲜明对比:在疾病晚期,载脂蛋白C-III水平似乎有所下降,晚期器官损伤可能是一个潜在的原因。需要进行孟德尔随机研究来证实或反驳这一假设。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical nutrition
Clinical nutrition 医学-营养学
CiteScore
14.10
自引率
6.30%
发文量
356
审稿时长
28 days
期刊介绍: Clinical Nutrition, the official journal of ESPEN, The European Society for Clinical Nutrition and Metabolism, is an international journal providing essential scientific information on nutritional and metabolic care and the relationship between nutrition and disease both in the setting of basic science and clinical practice. Published bi-monthly, each issue combines original articles and reviews providing an invaluable reference for any specialist concerned with these fields.
期刊最新文献
Skeletal muscle density as a new predictor of abdominal infection in abdominal trauma patients Effectiveness of N-3 fatty acids supplementation on spondyloarthritis: A systematic review and meta-analysis Reply–Letter to the Editor “Rethinking diet and cognitive health: Toward comprehensive methodological improvements” Unveiling the complex interplay between gut microbiota and polycystic ovary syndrome: A narrative review Letter to the editor - “Western diet-induced cognitive and metabolic dysfunctions in aged mice are prevented by rosmarinic acid in a sex-dependent fashion"
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1